Oncology Emerges as Pfizer's Growth Engine

Pfizer's cancer drug portfolio, led by Padcev and promising CDK4 inhibitor atirmociclib, offsets overall revenue decline, fueling investor optimism and strategic 2030 goals.

Pfizer's oncology division is becoming an increasingly critical component of its financial performance. As the company's overall revenue contracted slightly in 2025, its cancer drug portfolio is providing the growth narrative that investors are seeking.

Financial Performance: A Mixed Year

For the full year 2025, Pfizer reported revenue of $62.6 billion, representing an operational decline of 2% compared to the prior year. However, excluding COVID-19 products Paxlovid and Comirnaty, the underlying business grew by 6%. The fourth quarter of 2025 delivered a positive surprise, with earnings per share of $0.66 surpassing the analyst consensus estimate of $0.58. Quarterly revenue reached $17.6 billion.

Within the oncology segment, performance was notably strong. Biosimilars saw operational growth of 76% in Q4, while the cancer therapy Padcev posted a full-year operational increase of 15%.

Clinical Advancements Fuel the Pipeline

A significant clinical milestone was recently achieved with the selective CDK4 inhibitor, atirmociclib. In the Phase 2 FOURLIGHT-1 trial, the therapy met its primary endpoint. When combined with fulvestrant, it reduced the risk of disease progression or death by 40% in patients with HR+/HER2- metastatic breast cancer who had previously received other CDK4/6 inhibitors. This positions atirmociclib as a potential successor to current standard treatments in this area. A Phase 3 trial for first-line treatment is already underway.

This progress aligns with the company's stated strategic goal: to have more than eight blockbuster oncology medicines in its portfolio by 2030.

Institutional Interest and Future Catalysts

Alongside these developments, institutional investors have been increasing their stakes. In the third quarter, Hudson Bay Capital Management boosted its Pfizer position by approximately 1,785% to about 140,000 shares. Similarly, Park Avenue Securities raised its holdings by over 20% in Q4 to roughly 238,000 shares.

The current analyst consensus rating for Pfizer stock is "Hold," with an average price target of $28.14. More optimistic views include Argus Research, which maintains a "Buy" rating with a $35 target, and HSBC, which cites a $32 target.

Looking ahead, specific near-term catalysts from the pipeline are expected to influence the oncology division's trajectory. Pfizer plans a regulatory submission in the United States for vepdegestrant. Furthermore, continued development steps are anticipated for the antibody-drug conjugate sigvotatug vedotin in lung cancer.